A Parallel Group Phase I/II Marker Lesion Study to Assess the Safety, Tolerability and Efficacy of Intravenous or Intravesical Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 19 Mar 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Pembrolizumab (Primary)
Indications Bladder cancer
Focus Adverse reactions
Acronyms PemBla

Most Recent Events

16 Feb 2019 Results (n=4) of intravesical pembrolizumab evaluating safety and tolerability in recurrent non-muscle invasive bladder cancer were presented at the 2019 Genitourinary Cancers Symposium.
31 Aug 2018 Biomarkers information updated
14 Sep 2017 Planned End Date changed from 1 Apr 2021 to 1 Aug 2021.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight